Wave Life Sciences WVE 深 沪
等待开盘 08-10 09:30:00 美东时间
6.10
+0.080
+1.33%
华盛通- 最 高6.157
- 今 开6.15
- 成交量 455.64万股
- 最 低 5.92
- 昨 收 6.02
- 总市值 12.02亿
- 52周最高 21.73
- 市盈率 静 --
- 换手率 2.31%
- 52周最低 5.02
- 委 比 -20.44%
- 总股本 1.97亿
- 历史最高 56.00
- 量 比 1.89
- 振 幅 3.94%
- 历史最低 1.16
- 每 手 1
- 风险率 3.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has appointed David Butler, PhD, to its Strategic Advisory Board (SAB), bringing over 20 years of experience in oligonucleotide therapeutics, including siRNA and mRNA-based technologies. Butler, previously CTO at Hongene Biotech and with roles at Wave Life Sciences and Alnylam, will support Codexis' growth in enzymatic manufacturing. Carole Cobb is stepping down from the SAB after significant contributions. Codexis leverages its Cod...
08-03 13:00
美股大行评级 | 最高400美元！亚马逊绩后获11家大行上调目标价；苹果绩后评级分歧大！3家上调，3家下调；德康医疗、万事达、神经分泌生物科学获多家大行上调目标价
今日重点评级关注：TD Cowen：维持加拿大鹅"买入"评级，目标价从13美元升至18美元；瑞银：维持吉登运动服"买入"评级，目标价从110美元升至111美元
08-03 11:38
Wedbush Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $12
Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $15 to $12.
07-31 21:02
Wave Life Sciences posts Q2 results, pipeline update
The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sc...
07-30 19:57
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
Wave Life Sciences Ltd. has received shareholder approval for its proposed redomiciliation to the United States, subject to Singapore High Court approval. The company has filed an application for the Scheme of Arrangement, scheduled for a court hearing on July 14, 2026. Wave, a biotech company focused on RNA medicines, aims to unlock the potential of RNA therapies for various diseases. The company emphasizes its PRISM® platform and pipeline progr...
07-07 20:15
Wave Life Sciences Shareholders Approve Redomiciliation Scheme
An update from Wave Life Sciences ( ($WVE) ) is now available. On June 22, 2026...
06-26 20:59
Wave Life Sciences Initiates Phase 2a Multidose Portion Of INLIGHT Trial, Placebo-Controlled Study Evaluating WVE-007 As Monotherapy In Individuals Living With Obesity With High BMI And Comorbidities
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phase 2a portion in individuals with higher BMI and body fat, with and without type 2 diabetes, includes...
06-24 20:31
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
美股大行评级 | 最高1100美元，花旗、瑞穗、 Melius Research齐上调美光目标价；X-Energy获大小摩等多家机构首予“买入”评级
今日重点评级关注：TD Cowen：维持Strategy"买入"评级，目标价从395美元升至400美元；摩根士丹利：维持Cipher Digital"超配"评级，目标价从40.5美元升至42.5美元
05-20 11:55
